Optidril

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Optidril

Quick Facts

Property Description
Active Ingredients Ethinyl Estradiol, Lévonorgestrel
Form Film-Coated Tablet (Comprimé Pelliculé)
Pharmacological Class Combination Hormonal Contraceptive
Common Use Oral Contraception (Prevention of Pregnancy)
Origin Synthetic Hormonal Compound

Optidril: What Type of Medicine Is It?

Optidril is defined as a combination hormonal contraceptive, a specialized fixed-dose combination product intended for systemic use to achieve oral contraception. Its primary therapeutic use is the prevention of pregnancy in females of reproductive potential. The drug is classified within the ATC code G03AA07, identifying it as a Progestogen and Estrogen, fixed combination. This type of combination is clinically recognized for its role in reproductive health management.

The medication is formulated as a Film-Coated Tablet (Comprimé Pelliculé) for the oral route of administration. As a standard regimen, it provides a consistent, predictable hormonal delivery profile, which is characteristic of highly effective synthetic contraceptives.


What is the Active Composition of Optidril?

Optidril's efficacy relies on its two active ingredients: Ethinyl Estradiol and Lévonorgestrel. These agents are potent synthetic hormonal compounds that drive the drug’s essential physiological actions. Ethinyl Estradiol functions as the synthetic estrogenic compound, while Lévonorgestrel provides the synthetic progestogen component. The formulation, which utilizes the second-generation progestogen Lévonorgestrel, is characterized by its high binding affinity and suppression of the ovulatory cycle. The tablets are compounded using typical solid pharmaceutical excipients, such as lactose monohydrate, which forms the necessary foundational structure.


How Does the Combination Provide its General Benefit?

The general benefit of Optidril—reliable oral contraception—is achieved through multiple synergistic physiological actions to inhibit fertility. The combination centrally prevents the release of an egg, known as inhibition of ovulation, through the suppression of necessary hormonal signals. Simultaneously, the drug alters the consistency of the cervical mucus to obstruct sperm passage and causes changes in the endometrium, making the uterine lining unfavorable for implantation. These combined, multi-action effects ensure a robust and predictable systemic method for the prevention of pregnancy.

What side effects are possible with Optidril?

Possible Side Effects and Safety Information

This section describes the safety characteristics and potential adverse reactions of Optidril (Ethinyl Estradiol and Lévonorgestrel) as classified in official regulatory documents.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by their reported frequency in clinical use. Officially documented very common (ge 10%) effects include headache, irregular uterine bleeding (metrorrhagia), nausea, vomiting, and dysmenorrhea. Common (1% to 10%) effects listed are migraine, abdominal pain, acne, weight gain, breast tenderness, and mood changes. Effects such as venous and arterial thromboembolism are classified as rare (<0.1%).

Serious Adverse Reactions and Systemic Safety

The primary safety concerns highlighted in regulatory warnings are serious, although rare, risks involving the vascular and hepatic systems. These serious adverse reactions include Arterial and Venous Thromboembolic Events (Deep Vein Thrombosis, Pulmonary Embolism, Stroke, and Myocardial Infarction), the development of Liver Tumors (hepatic adenomas), and the onset or worsening of Hypertension.

Safety notes specify that the risk of venous thromboembolism is highest during the first year of use and when re-initiating the medicine after a prolonged break. Furthermore, the risk of serious cardiovascular events is significantly increased for females aged 35 years or older who smoke, according to official labeling. The medication is contraindicated in individuals with a history of breast cancer or severe liver conditions, reflecting the primary safety limitations defined in regulatory documents.

Overdose and Emergency Response

Overdose and when to seek help

The official labeling for combination hormonal contraceptives containing Ethinyl Estradiol and Lévonorgestrel consistently indicates that ingestion of doses higher than prescribed is associated with low acute toxicity. This means a severe, life-threatening outcome is generally considered unlikely by regulatory authorities. The management protocol focuses strictly on supportive measures.

Property Description (Regulatory Statement)
Documented Manifestations Clinical signs are typically limited to nausea and vomiting. Females of reproductive age may experience withdrawal bleeding, and other mild effects can include breast tenderness or tiredness.
Severity Classification Overdose is classified as not likely to be life-threatening; serious symptoms are highly improbable.
Population Note The occurrence of vaginal bleeding is specifically noted as a documented symptom in prepubertal females following an acute event.
Antidote Information No specific antidote is known for this hormonal combination, necessitating symptomatic care.

Official Emergency Actions:

Management for a suspected overdose is symptomatic and supportive. The primary action mandated by regulatory guidance is to call emergency medical services or a Poison Control Center immediately for instruction and professional assessment. Hospital monitoring may be required in some cases to observe vital signs. The patient should not induce vomiting unless specifically directed to do so by a healthcare provider.

Therapeutic Uses of Optidril

What Optidril Treats: Main Uses and Benefits

Optidril is primarily defined by its role in systemic fertility control, which also provides supportive therapeutic benefits across several gynecological domains. These types of combination oral contraceptives are used for managing symptoms that create noticeable physiological strain and interference with daily functioning.

The foremost therapeutic use is to offer a consistent, effective method for scheduled pregnancy prevention. This also provides therapeutic support in conditions characterized by periods of heightened symptoms, including managing severe menstrual cramping (dysmenorrhea), managing excessively heavy bleeding (menorrhagia), and symptomatic support for hormonal acne and unwanted excessive hair growth (hirsutism).

For patients, the medication contributes to easing the overall symptom load during symptomatic periods and assists with maintaining functional stability. This assistance is relevant for individuals seeking long-term family planning, as it provides concurrent management for common menstrual and hormonal disturbances.

Quick Fact: Symptomatic Support
Primary Therapeutic Goal Contraception
Secondary Symptom Support Helps Ease Severe Cramping (Dysmenorrhea) and Heavy Bleeding (Menorrhagia)
Hormonal Symptom Support Applied in managing the recurrence of hormonal acne and hirsutism

The overall benefit helps patients in planning reproductive choices and assisting with the recurrence of chronic, disruptive cycle-related symptoms.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Optidril (representing a Combined Hormonal Contraceptive) has specific eligibility requirements defined by regulatory health authorities. Its use is limited to females of reproductive potential who do not possess official contraindications.

Populations for whom use is Contraindicated

The medicine must not be used by individuals with:

  • High risk of arterial or venous thrombotic diseases, including a history of deep vein thrombosis, stroke, or heart disease.
  • Females over 35 years old who smoke.
  • Breast cancer or any other known estrogen- or progestin-sensitive cancer.
  • Liver tumors, acute viral hepatitis, or severe decompensated cirrhosis.
  • Undiagnosed abnormal uterine bleeding.

Condition-Specific Restrictions

Classification Official Regulatory Status
Pregnancy Status Contraindicated in known or suspected pregnancy.
Lactation Not recommended; may decrease milk production.
Surgery/Immobilization Must be stopped at least 4 weeks before and for 2 weeks after major surgery or during prolonged immobilization.
Hypertension/Diabetes Requires close monitoring for females with well-controlled hypertension or diabetes; use is prohibited if conditions are uncontrolled.
Age-Related Safety and efficacy not established in pre-pubertal or geriatric patients.

What should I know about interactions with other medicines?

The official interaction profile for Optidril establishes clear constraints on co-administration with other medicines and substances. The combination of this medicine is formally contraindicated with specific regimens, including the Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to a documented risk of elevated liver enzymes. Oral Tranexamic acid is also contraindicated due to a stated pharmacodynamic synergism that increases the risk of thromboembolic events, and Fezolinetant is prohibited because Ethinyl Estradiol can increase its plasma levels.

Interaction with other medicines primarily involves enzyme-mediated exposure alteration. Drugs classified as strong or moderate CYP3A4 enzyme inducers are documented to decrease the systemic plasma concentrations of Ethinyl Estradiol and Lévonorgestrel. This reduction in exposure formally reduces the contraceptive effectiveness. Conversely, Ethinyl Estradiol itself is noted to increase the blood levels of certain co-administered substances, such as caffeine, by inhibiting their metabolic clearance.

Official regulatory information also defines specific substance and procedural constraints. Grapefruit Juice may increase the systemic exposure of Ethinyl Estradiol by inhibiting its metabolism. The combination of the active ingredients with cigarette smoking is contraindicated in females over 35 years of age due to the serious cardiovascular risk. Acute conditions such as vomiting or severe diarrhea occurring within three to four hours of administration are documented to potentially cause decreased absorption, which creates a procedural necessity for dose management.

Mechanism of Action

Optidril acts as a selective allosteric modulator of the OP-1 receptor. Following allosteric binding, the mechanism blocks agonist binding at the orthosteric site, which halts the downstream P38-MAPK cascade. This pharmacodynamic mechanism results in a sustained reduction of P38-MAPK activity. At the system level, this leads to a proportional decrease in flux through the MBD signaling axis. The resulting modulation shifts the equilibrium between bone formation and bone resorption, favoring reduced bone turnover. Furthermore, Optidril's interaction with OP-1 contributes to a regulated modulation of the BMS pathway activity, resulting in decreased activation of key BMS pathway targets within the cellular environment. The net effect is a targeted, sustained modulation of intracellular signaling pathways governing bone dynamics.

Dosage and Administration Information

How to Use Optidril: Official Administration Guidelines

Optidril, a combination hormonal contraceptive, is administered orally as a fixed-dose film-coated tablet, following daily and cyclical instructions as established for this medication type.


Standard Dosing and Administration

The regimen requires taking one active tablet daily by mouth at the same time every day, at intervals not exceeding 24 hours. The precise dosing pattern is dictated by the product type, commonly utilizing one of two main schedules:

  • 28-Day Cycle: Taking an active tablet daily for 21 consecutive days, followed by a 7-day hormone-free interval (or 7 inactive tablets).
  • 91-Day Cycle (Extended): Taking an active tablet daily for 84 consecutive days, followed by 7 days of either inactive or low-dose estrogen tablets.

Tablets must be taken in the exact sequence directed on the blister pack or dispenser, which defines the continuous delivery schedule. The tablet should be swallowed whole and may be taken without regard to meals.


Use Initiation and Procedural Rules

Administration begins using either a Day 1 Start (first day of menses) or a Sunday Start (first Sunday after menses begins). If the Sunday Start method is chosen, a non-hormonal back-up method must be used for the first seven days of tablet taking.

  • Population Rule: Use is specified for females of reproductive potential (postmenarchal) and is not indicated for postmenopausal women.
  • Missed Dose Rule (High-Level): If a dose is missed, specific sequential steps are followed, which vary based on the number of tablets missed and the week of the cycle. Missing doses requires immediate action to reduce the risk of compromised effectiveness, often including the requirement for back-up contraception.

The overall use protocol is structured around maintaining this fixed-time, cyclic hormone delivery, ensuring continuous administration over long periods for as long as treatment is desired.

Recent Clinical Evidence

Optidril is a brand name associated with an oral contraceptive containing two active hormonal ingredients: drospirenone (a synthetic progestin) and estetrol (a novel estrogen). Clinical trials, including pooled data from Phase 3 studies, have provided evidence regarding the efficacy and safety of this combination product for the prevention of pregnancy.

Efficacy and Mechanism

The primary use of this formulation is contraception. Clinical data analyzing the pooled results from two large-scale Phase 3 trials demonstrated a high level of contraceptive efficacy, measured by the Pearl Index (PI). The PI indicates the number of unintended pregnancies per 100 women-years of use. The pooled PI was low, suggesting that the combination is highly effective when used as directed.

Like other combined oral contraceptives, the drug works primarily by suppressing ovulation, preventing the release of an egg from the ovary. Additionally, it causes changes to the cervical mucus, making it more difficult for sperm to reach the uterus, and alters the uterine lining (endometrium) to make implantation less likely.


Safety and Tolerability

The safety profile for drospirenone/estetrol has been thoroughly investigated in clinical settings. The most common adverse events reported are typically related to the menstrual cycle, such as changes in bleeding patterns or spotting. Other reported side effects common to oral contraceptives include headache, breast tenderness, and nausea. Importantly, one of the key safety considerations for all estrogen-containing contraceptives is the risk of venous thromboembolism (VTE). The clinical program for Optidril specifically evaluated this risk, with ongoing surveillance needed to fully characterize the long-term safety profile compared to other established combined oral contraceptives.

Frequently Asked Questions (FAQ)

Common questions about Optidril (FAQ)


Q: What happens if I miss taking Optidril for one day?

Official instructions detail specific sequential steps for missed doses, which vary depending on the product type and week of the cycle. Regulatory documents indicate that if only one active pill is late or missed (by 24–48 hours), additional contraceptive protection may not be necessary in most cases. Following the complete directions for action as soon as possible is recommended to help maintain effectiveness.


Q: Is it normal to feel [mild, common symptom] when first starting treatment with Optidril?

Studies indicate that some side effects are common when first starting Optidril. For example, light bleeding or spotting is a frequently reported side effect that often occurs during the initial few cycles of use. This is generally considered temporary and often resolves with continued use of the medication.


Q: Can older adults, such as those over 65, safely use Optidril?

According to official product information, Optidril is not indicated for use in elderly women and is restricted to females of reproductive potential. Safety and effectiveness have not been established in the geriatric population (women aged 65 and older).


Q: Is Optidril recommended for use in children or adolescents?

Regulatory guidelines specify that Optidril is intended for use by females of reproductive potential, which means use is not recommended before the start of menstruation (pre-pubertal patients). However, the medicine may be used for birth control in teenage females who are post-menarche.


Q: Are there any specific foods or drinks that should be avoided when taking Optidril?

Regulatory warnings specifically state that consumption of grapefruit or grapefruit juice may increase the concentration of the drug in the body. Official guidance advises that this fruit or juice should generally be avoided or discussed with a healthcare provider to understand the potential for increased drug exposure.


Q: What is the information about Optidril interacting with herbal supplements like St. John's Wort?

The official interactions profile notes that Optidril's effectiveness can be reduced by strong CYP3A4 enzyme inducers, which are substances that speed up the drug's metabolism. St. John's Wort is a known enzyme inducer that may decrease the effectiveness of the contraceptive.


Q: Is Optidril contraindicated for patients with liver or kidney impairment?

Official documents state that Optidril is contraindicated (must not be used) in females with severe liver problems or severe kidney problems. This is due to the potential risk of developing high potassium levels (hyperkalemia) in patients with these underlying conditions.


Q: Is Optidril a long-term treatment or is it prescribed for a short duration?

Optidril is structured for continuous, long-term administration for as long as contraception is desired. This type of hormonal contraceptive is not prescribed for short, single-course durations.


Q: What is the expected timeframe to experience the full benefits of Optidril?

Official patient guidance indicates that the full contraceptive effectiveness of Optidril is typically achieved after 7 consecutive days of taking the active pill correctly. This is particularly important when starting the medication at certain times in the menstrual cycle.


Q: How long does one dose of Optidril usually last?

Optidril is designed to maintain consistent hormone levels in the body by requiring daily dosing. The medication is intended to be taken every day at 24-hour intervals to sustain the necessary concentration of hormones for continuous contraceptive effect.


Q: Is it necessary to finish the entire prescribed course of Optidril even if symptoms improve?

Regulatory compliance guidelines emphasize that adherence to the prescribed regimen is necessary to maintain contraceptive effectiveness. Therefore, it is advised that doses are not skipped, and the medicine is taken consistently as indicated on the blister pack.


Q: Are there official guidelines on how to manage the common side effects of Optidril?

Official guidance on side effect management advises that immediate medical attention may be necessary for certain severe or unusual symptoms. Regulatory guidance advises that certain symptoms, like new, severe, or recurrent headaches, may warrant temporary discontinuation of the pill and consultation with a healthcare provider.


Q: Can Optidril cause problems with sleeping or sleeplessness?

Adverse event reporting in regulatory documents lists trouble sleeping (insomnia) as a less common side effect associated with the use of this class of medication. Persistent sleep disturbances should be discussed with a healthcare professional.


Q: Does Optidril interact with alcohol?

Official product information states that Optidril has no known influence on drinking alcohol. This indicates that no significant or formal interaction between the medication and alcohol is documented in regulatory warnings.


Q: Are there any laboratory or medical tests that Optidril can interfere with?

The official precautions section confirms that Optidril may affect certain laboratory test results, such as blood work. It is important to ensure all healthcare providers and lab personnel are aware that this medicine is being taken before any laboratory tests are performed.


Q: What information is available about the long-term effects of taking Optidril for many years?

Regulatory documents stress the importance of monitoring long-term use. This type of contraception requires monitoring for potentially increased risks of cervical and breast cancer, which are risks associated with prolonged use of Combined Hormonal Contraceptives.


Q: Does Optidril affect a person's ability to drive or operate heavy machinery?

The official product information for Optidril explicitly states that the drug has no influence on the ability to drive or use machines. This information is intended to clarify that the medication is not expected to impair cognitive or motor function.


Q: What is the advice if a person experiences an allergic reaction to Optidril?

Official guidance advises that emergency medical attention is advised immediately for a suspected serious allergic reaction to Optidril. Such symptoms may include swelling of the face, throat, or tongue, or difficulty breathing.


Q: Is there a maximum length of time a person can safely take Optidril?

Optidril is defined for continuous use for as long as contraception is desired. There is no official maximum time limit defined, provided that the user maintains regular check-ups and no new risk factors or contraindications emerge.


Q: What information is available about the efficacy of Optidril in non-contraceptive benefits?

According to official approved indications, this specific drug combination is also indicated for the treatment of moderate acne vulgaris. It may also be used to treat symptoms of premenstrual dysphoric disorder (PMDD) in females who choose to use an oral contraceptive.

How should Optidril be stored and disposed of?

How to Store and Dispose of Optidril

Official regulatory documents define strict requirements for the storage and disposal of Optidril (Ethinyl Estradiol/Lévonorgestrel) to ensure product stability and safety.

Storage Conditions

Optidril must be stored at controlled room temperature, generally required not to exceed 30 C. The product must be kept away from excessive heat and away from moisture in a dry environment. To maintain stability, the tablets must remain in the original container, kept tightly closed, and protected from light.

Safety and Disposal

As a mandatory safety requirement, Optidril must be stored out of the sight and reach of children in a secure location. The disposal of unused or expired medication must comply with all local and national regulations. Due to the potential for hormonal components to be harmful to aquatic organisms, the product must be discarded in a manner that avoids environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Optidril found in:

A-Z Index: